Skip to content
Open access

Refractory anti-SAE positive dermatomyositis: a case report characterized by bullous phenotype, severe dysphagia, and progressive calcinosis

Oct 2026 · ANPAbstract_CBN26 · 0 citations

Abstract

Case Presentation: A previously healthy 27-year-old female presented in 2016 with diffuse pruritus, predominantly involving the scalp, upper limbs, and chest, which rapidly evolved into generalized hyperemia. Within four weeks, she developed symmetric proximal weakness, with impairment in climbing stairs. Simultaneously, papular lesions on the face and scalp that atypically progressed to a bullous presentation were noticed. By the third month, the patient was unable to stand unaided with a severe dysphagia, suggesting critical bulbar-inervating muscles involvement. Our first evaluation took place five months after the onset, and the neuro exam highlighted a heliotrope rash, V-sign, and residual bullous lesions. Despite the severity of the weakness, CPK levels remained consistently within normal limits. Diagnostic workup revealed interstitial dermal mucinosis on skin biopsy and a diffuse myopathic pattern with irritative activity on electroneuromyography. Following a diagnosis of Dermatomyositis (DM), management began with high-dose corticosteroids and methotrexate, yielding initial clinical stabilization. Two years later, the patient experienced a relapse marked by refractory pruritus and the development of extensive abdominal calcinosis. Despite the treatment shift to Mycophenolate Mofetil and Hydroxychloroquine, the disease remained corticosteroid-dependent (dose reduction-induced flares occurred without significant CPK elevation arround 90 U/L). Rituximab was initiated as a corticosteroid sparing strategy. Serological profiling available only in 2025 confirmed Anti-SAE (Small Ubiquitin-like Modifier Activating Enzyme) antibodies with weak anti-Mi2 positivity. Discussion: The rarity of this case lies in the Anti-SAE serotype, which accounts for only 3–8% of DM patients and is intrinsically linked to aggressive cutaneous manifestations and a high incidence of dysphagia, often contrasted by disproportionately low muscle enzyme levels. While anti-Mi2 antibodies typically suggest a favorable prognosis, the dominant Anti-SAE phenotype drove the refractory course and the development of calcinosis—a debilitating complication notoriously resistant to standard immunosuppression. Furthermore, the persistent weakness despite near-normal CPK levels poses a diagnostic challenge, necessitating a distinction between residual inflammatory activity and glucocorticoid-induced myopathy. Final Comments: Given the paraneoplastic potential associated with this molecular subgroup, ongoing screening for breast malignancy remains mandatory. This case underscores the necessity of early serological profiling in DM to predict aggressive clinical phenotypes and the role of B-cell depletion therapy in refractory cases. Beyond immunosuppression, a multidisciplinary approach focusing on rehabilitation and mental health is imperative to manage the non-motor symptoms that drastically impairs the quality of life.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.